{
  "trial_id": "NCT00194896",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "was explained and informed consent obtained",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "autoantibodies, glucose, C peptide of proinsulin molecule (C-peptide), glycosylated hemoglobin (HbA1c), genetic typing, and T lymphocyte (T cell) responses to islet antigens.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The beta cell function test was performed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All patients were encouraged to perform self blood glucose monitoring twice per day, before breakfast and before dinner",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The treatment goals for all patients was the same: before breakfast and before dinner blood sugar levels between 90-130 milligrams per deciliter (mg/dI) and HbA1c of less then 7% without severe hypoglycemia",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Patients unable to reach goal with monotherapy had metformin (initially) or acarbose (secondarily) added",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "The rosiglitazone treatment group commenced therapy with 4 milligram (mg) once per day and increased to twice per day if adequate glycemic control was not achieved",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "For glyburide, therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "If adequate control, HbA1c less than 7%, was not achieved on glyburide or rosiglitazone monotherapy, metformin was added and the dose gradually increased as needed and tolerated to a maximum of 1000 mg twice daily",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Age at onset of diabetes - 35-69 years old",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "No history of ketonuria or ketoacidosis",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Not requiring insulin to achieve glycemic control",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Fasting c-peptide greater than or equal to 0.8 ng/ml",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with history of chronic pancreatitis or other secondary causes of diabetes",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Creatinine greater than 1.4 or liver enzymes greater than 2 times the upper limits of normal",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "The patient is a 24-year-old man with type 1 diabetes who has had previous episodes of diabetic ketoacidosis, but currently appears well and does not have any nausea, vomiting, or abdominal discomfort.",
  "_meta": {
    "topic_id": "29",
    "trial_id": "NCT00194896",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}